Intravenous Vitamin C is a therapy for cancer with a history that began with the research of Dr. Linus Pauling PHD, and Dr. Ewan Cameron MD in the 1970′s.  Dr. Pauling and Dr. Cameron found that using a combination of intravenous vitamin C and orally dosed vitamin C led to improved survival in the cancer patients they were studying.  A follow up study could not duplicate the results, but that study only used oral dosing of vitamin C.

 

What more current scientific literature has shown is that vitamin C administered intravenously (directly into the bloodstream with an IV needle) results in concentrations of vitamin C in the blood and tissues of the body that cannot be achieved through oral dosing (taking capsules by mouth).

 

Research has also shown that vitamin C at these higher doses can by toxic to cancer cells via a pro-oxidant process which causes damage to cancer cells.  Vitamin C converts to a molecule called hydrogen peroxide which then causes damage selectively to cancer cells.  Many cancer cell lines from a variety of cancer types (pancreatic, breast, ovarian, lymphoma, glioblastoma, and others) are deficient in an enzyme called catalase which breaks down hydrogen peroxide, and this makes them susceptible to vitamin C therapy.  Normal cells are not deficient in this enzyme and so are not harmed by the therapy.  This makes intravenous vitamin C a relatively safe treatment which has the potential to selectively kill cancer cells.

In Dr. Denis’ clinical practice, he has seen intravenous vitamin C:

  • act as a selective and relatively safe directly anti-cancer chemotherapy agent
  • improve tolerability and effectiveness of certain conventional chemotherapy agents
  • improve quality of life – patients often say they have a greater sense of well being

 

Dr. Denis has seen these benefits in many different types of cancers and stages.

 

Research

 

The following article offers a good review of the current understanding of intravenous vitamin C for cancer:

 

And this article details the effects of intravenous vitamin C on various cancer cell lines xenografted in mice.

 

 

 

Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy.

 

Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany.

 

Intravenous ascorbic acid(vitamin C) administration in myomectomy: a prospective, randomized, clinical trial.


Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects.